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S292 Poster Session I(40%) were females. 23 (53.5%) had high risk cytogenetics and 19
(44%) had non-denovo AML. There was no statistically significant
difference in cytogentic risk (p 5 0.56) or diagnosis of non denovo
AML (p 5 0.18) between the transplant and the non transplant
groups.
Outcomes: CR rate including CR without platelet recovery (CRp)
was 88 % with no induction related deaths. Of the 38 patients who
went into remission 7 (18%) relapsed at a later time point. Median
follow up of the entire cohort was 181days (24 to 987). 20 (47%) pa-
tients were able to proceed to transplant, 6 underwent autologous
SCT, 12 underwent allogeneic SCT and 2 underwent autologous
SCT followed by an allogeneic SCT at relapse. The median time
to first SCT since induction was 115 days (32 - 195). Median OS
was 11.3 months. Median OS of the patients who underwent SCT
is *not reached vs 5.1 months for the non transplant group (p 5
0.0055). Median PFS of patients who underwent SCT was *not
reached vs 5.9 months for the non transplant group, (p 5 0.0229).
Conclusions: In this high risk AML population, HiDAC/MITO in-
duction was well tolerated and demonstrated an excellent CR/CRp
rate of 88% with no induction deaths. Substantial number (47%)
of patients proceeded to SCT and had a significantly better outcome
(both OS and PFS).237
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN THE
ELDERLY PATIENTS (AGE . 65 YEARS) WITH ACUTE MYELOID
LEUKEMIA (AML) IS SAFE AND EFFECTIVE
Jagadeesh, D.1,2, Cerny, J.1,2, Ramanathan, M.1,2, Raffel, G.D.1,2,
Petrillo-Deluca, L.2, Tarrasky, N.2, Krumpe, L.M.2, Bednarik, J.2,
Barton, B.A.1, Walsh, W.V.1,2, Nath, R.1,2 1Univeristy of Massachusetts
Medical School, Worcester, MA; 2UMass Memorial Medical Center,
Worcerster, MA
Introduction: AML patients over age 65 years have a poor outcome
with a median survival of 2 months and a 2-year survival rate of 6%
(Menzin et al Arch Intern Med. 2002). Allo-SCT is curative in AML
but is frequently not offered to older patients because of the concern
of high mortality associated with this procedure.
Methods: Retrospective analysis was performed on all patients with
AML over age 65 years who underwent an allo-SCT at UMass Me-
morial Medical Center since 2009. The study was approved by
UMass Memorial Medical Center IRB.
Results: 9 patients were identified from the database. There were 6
men and 3 women. Median age at SCT was 69 years range (65-78). 4
patients were$70 years of age. Disease status at SCT was complete
remission (CR) in 4 (44%) and persistent disease in 5 (56%) patients.
Median number of chemotherapy cycles prior to SCT was 3 range
(1-14). 1 patient had 2 prior autologous SCT. 5 (55%) patients
had poor prognostic cytogenetics (including Flt-3 ITD) and 6
(67%) patients had preceding MDS. Median time from diagnosis
to SCT was 197 days range (105-2240). Stem cell source was single
cord blood (CB) unit in 3 and unrelated donor in 6 patients. Prepar-
ative regimen was myeloablative in 4 (Thiotepa10mg/kg/Flu/Mel
140mg/m2/rabbitATG in 3 CB-SCT; Flu/Bu3.2mg/kg x 3/ATG
in 1) and reduced intensity in 5 patients (Flu/Bu3.2mg/kg x 2/
ATG). Graft versus host disease (gvhd) prophylaxis was tacroli-
mus/mycophenolate mofetil (MMF) in 6 and sirolimus/MMF in 3
subjects.Median number of stem cell infusedwas 4.99 x106 /kg range
(1.7 x105- 6.14 x106). All 9 patients engrafted with full donor chime-
rism and were in CR post SCT.Median time for neutrophil engraft-
ment was 18 days range (13-41) and platelet engraftment was 13 days
range (11-73). Grade II-IV acute gvhd developed in 2 patients. Day
100 survival was 8/9 (89%). The Kaplan-Meier Product-Limit esti-
mates show that the long-term survival probability is 0.78 and is sta-
ble at that level after 6 months. Four patients have survival times
longer than one year with two patients surviving beyond two years.
No patient relapsed post SCT. All surviving patients have Karnofsky
performance score $80. 2 patients are off all immunosuppressant
therapy.
Conclusion: Allogeneic SCT is safe and effective treatment modal-
ity for elderly AML patients. This treatment modality needs to be
validated in prospective clinical trials.238
EFFECT OF PRE-TRANSPLANT CHEMOTHERAPY BEFORE HUMAN
LEUKOCYTE ANTIGEN IDENTICAL SIBLING TRANSPLANTATION FOR
ACUTE MYELOGENOUS LEUKEMIA IN FIRST COMPLETE REMISSION
Ghavamzadeh, A., Hoghooghi, M., Jahani, M., Alimoghaddam, K.,
Mousavi, S.A., Bahar, B., Iravani, M., Jalili, M., Jalali, A. Tehran Uni-
versity of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Pre-transplant consolidation therapy for patients with
AML in the first complete remission (CR) decreases leukemia recur-
rence and improves survival.
Patients and Methods: 29 AML patients (15 females and 14 males)
with a median age of 33 years (range 18-63) enrolled from Feb. 2010
to Oct. 2011 were randomly allocated into two groups. 14 patients in
the first group (A) received 7+3 chemotherapy regimen (cytarabine
100mg/m2/day for 7 days+ idarubicin 12mg/m2/day for 3 days) prior
to hematopoietic stem cell transplantation (HSCT) and 15 patients
in the second group (B) received 7+3 regimen followed by 5+2 (cytar-
abine 100mg/m2/day for 5 days+ idarubicin 12mg/m2 for 2 days) be-
fore HSCT. All Patients were in complete remission before
transplantation. Peripheral blood stem cells were the preferred
source for transplantation.
Results: The median time from diagnosis to transplant was 70.5
days in the B and 171 in the A group. The median time to absolute
neutrophil count $ 0.5*10^9/L was +13 days in the B and + 14
in the A group (p 5 0.18). The median time to platelet count $
20000 was +15 days in the B and +16 in the A group (p5 0.32). Me-
dian follow-up time was 128 days. Acute GVHD occurred in 7
(46.7%) patients in the B and in 11 (78.6%) patients in the A group.
Themost common grade of acute GVHDwas grade II for 3 (42.9%)
and 8 (72.7%) patients in the B and A groups, respectively. At this
time, 24 patients (82.3%) are still alive (13 in the B & 11 in the A
group). The causes of death were GVHD in 3 patients (1 in the B
and 2 in the A group), relapse (1 patient in the B group) and CMV
infection (1 patient in the A group). 4-month overall survival was
92.3% (SE: 7.4%) and 80% (SE: 12.6%) in the B and A groups, re-
spectively (p5 0.4). 4-monthLeukemia-free survival was 82.1% (SE:
11.7%) in the B and 80% (SE: 12.6%) in the A group (p 5 0.64).
The cumulative incidence of acute GVHD on +12 days was 20%
(95% C.I.: 5%-43%) in the B and 64% (95% C.I.: 32%-84%) in the
A group that was statistically significant (p 5 0.032).
Conclusion: Preliminary results show that omitting consolidation
therapy prior to hematopoietic stem cell transplantation has no ad-
verse impact on survival outcome in short-term follow-up of pa-
tients, but reduces the cumulative incidence of acute GVHD after
transplantation. More cases and longer duration of follow-ups are
needed to achieve significant results.239
STEM CELL TRANSPLANT (SCT) OVERCOMES THE POOR PROGNOSIS AS-
SOCIATED WITH CD25 EXPRESSION IN ACUTE MYELOID LEUKEMIA
(AML): ARETROSPECTIVE SINGLE CENTER ANALYSIS
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Petrillo-Deluca, L.J.1, Tarrasky, N.1, O’Rourke, E.1, Bednarik, J.1,
Hao, S.2, Hutchinson, L.2, Woda, B.2, Barton, B.3, Rosmarin, A.G.1,
Nath, R.1 1University of Massachusetts Medical School, Worcester, MA;
2University of Massachusetts Medical School, Worcester, MA; 3University
of Massachusetts Medical School, Worcester, MA
We have recently identified that expression of CD25 on leukemic
blasts as a novel prognostic marker associated with high relapse rate
and short relapse free survival (RFS). CD25+ was a more robust pre-
dictor of AML relapse (multivariate Cox regression analysis HR 6.54
[1.34-9.15], p 5 0.01; FLT3-ITDmut: HR 4.72 [2.04-10.92], p 5
0.03). CD25+ leukemic cells resembled behavior of leukemic stem
cells (LSCs) as described by Saito et al (Sci Transl Med 2010). We
report the effect of stem cell transplantation (SCT) on outcome of
pts with CD25+ AML.
We retrospectively examined the impact of SCT in 46 AML pa-
tients eligible for induction therapy (excluding APL) in whom
CD25 was assessed.
Median age was 61 years (range, 22-84); 19 were (41%) female.
CD25 was detected in 17 pts (37%). No difference was seen in the
following factors: gender, age, cytogenetics, or presence of
Poster Session I S293NPM1mut; whereas 65% of pts with CD25+ AML had FLT3-ITD-
mut (p5 0.0012). The total of 24 (53%) pts received stem cell trans-
plantation (SCT), 9 (38%) of those were CD25+. Median time from
diagnosis to SCT was 4 months (2-7). At the time of SCT 5 (21%)
CD25+ pts were in CR1 and 4 (17%) were in CR2 or had refractory
disease compared to 14 (58%) CD25- pts in CR1 and 1 (4%) pt had
relapse (p 5 0.047). The RFS was significantly inferior in CD25+
AML pts compared with CD25- pts (6-month; 26% vs 79%; p 5
0.0003). This did not translate into a statistical difference in OS
(1-year; 43% vs 65%; p5 ns). CD25+ pts who received SCThad sig-
nificantly superior 1-year OS (63%) vs CD25+ pts who did not un-
dergo SCT (0%; p 5 0.0098).
In our experience, treatment with SCT appeared to eliminate the
negative impact of CD25 expression. Prospective validation of the
prognostic impact of CD25 in AML is warranted.240
A NOVEL RE-INDUCTION THERAPY CLOFARABINE, CYCLOPHOSPHA-
MIDE, BORTEZOMIB, DEXAMETHASONE, ETOPOSIDE (CCBDE) FOR RE-
LAPSED AND REFRACTORY ALL
Morris, C.L., Morris, J., Brown, B., Bedros, A. Loma Linda University
Medical Center, Loma Linda, CA
Background: Despite advances in treatment of pediatric leukemias,
the prognosis with recurrent disease remains poor. Transplantation
is the treatment of choice for relapses within a year of completing
therapy. In order for transplantation to be successful, the patient
must be in a solid remission.
Methods:We treated 7 pediatric patients (age 1-16 years, median 9)
with relapse ALL that failed standard induction therapy(s). Patients
received clofarabine (40mg/m2/day) days 2 to 6, cyclophosphamide
(400mg/m2/day) days 2-6, bortezomib (1.1mg/m2/day) days 1, 4, 8,
11, Dexamethasone (20mg/m2/day) days 1-6, 8, 11, etoposide
(150mg/m2/day) days 2-6 (CCBDE).
Results: 5/7 patients (71%) achieved a CR after 1 (4) or 2 (1) courses
of CCBDE. All patients had failed 1-4 cycles of standard induction
chemotherapy prior to attempting CCBDE: 2 patients received
COG AALL01P2 plus clofarabine-cyclophosphamide-etoposide in
1, 2 COG ADVL04P2 plus mitozantrone-cytarabine in 1, 2 induc-
tion failures on COG AALL0232 and COG AALL0631, and 1
post-BMT relapse with history of poor response to AALLO1P2.
Two patients had relapsed 3 and 6months after SCT.Despite exten-
sive prior therapy marrow recovery after 1 cycle of CCBDE was
prompt (18-20 days) in non-transplant patients and 40-50 days for
post-SCT.Minimal residual disease (MRD)was\1025 in 4 of the re-
sponders. Three patients had unrelated donor SCT’s. Two died of
toxicity, and one survives 22 months after SCT. Two patients are
in remission awaiting transplant, one has been in continuous remis-
sionwith negativeMRD for 1 yearwithout additional chemotherapy.
Two patients did not respond to CCBDE; 1 had received a prior clo-
farabine regimen and 1 achieved remission with VPLD plus borteza-
mib and went on to a second SCT but relapsed 9 months later.
Conclusion: CCBDE regimen is a novel promising re-induction
chemotherapy regimen for relapsed and refractory ALL. Given the
extensive prior therapy these patients had received the regimen was
well tolerated. Among responders marrow recovery was prompt
for non-transplant patients but more delayed in early post transplant
patients, in this small series. Most responders (4/5) had extremely
deep remissions and none of these have relapsed while awaiting
transplant. We continue to investigate the efficacy of this regimen
and consider the addition of other agents with non-overlapping tox-
icities to improve its effectiveness.241
CLOFARABINE FOR CYTOREDUCTION PRIOR TO ALLOGENEIC TRANS-
PLANT CONDITIONING FOR REFRACTORY ACUTE MYELOGENOUS
LEUKEMIA
Jeyakumar, D., Sprague, K., Miller, K.B., Klein, A., Klingemann, H.
Tufts Medical Center, Boston, MA
Treatment of primary refractory and relapsed refractory AML is
unclear. We report a retrospective analysis of all patients whoreceived clofarabine for refractory AML immediately prior to alloge-
neic stem cell transplantation between 2006 and 2011. Eleven pa-
tients with refractory AML received clofarabine 40 mg/m2 with or
without cytarabine 100mg/m2 prior to AlloSCT. Nine patients
had primary refractory disease, 2 were in first relapse. Median age
was 62. Three patients had de novo AML, 7 prior MDS, 1 prior P.
Vera. One patient had a prior autologous SCT. Cytoreduction
with\10% marrow blasts was achieved in 44%. Two patients died
prior to transplant due to infection. At time of transplant, 6 patients
(66%) had infectious complications. Three patients (33%) had
documented bacteremia prior to transplant. Of the 9 patients who
proceeded to AlloSCT, 6 received RIC with extracorporeal photo-
pheresis for 2 days, Pentostatin 4mg/m2 x 2 days and 600 cGy frac-
tionated TBI. Three patients received myeloablative conditioning: 2
with Cytoxan/TBI 1200 cGy, 1 with Busulfan/Cytoxan. Grade I-II
hyperbilirubinemia and Grade I-II transaminitis were documented
in 4 patients (44%) and 5 patients (55%) after clofarabine prior to
transplant, respectively. Grade I aGvHD occurred in 5 patients
(55%) and grade II aGvHD in 2 patients (22%). No patient devel-
oped Grade III or IV aGvHD. The 100 day transplant-related mor-
tality was 1/3 (33%) and 4/6 (66%) in the RIC group and in the
myeloablative conditioning group, respectively. One patient died
of sinusoidal obstruction syndrome on day 20. The 100 day overall
survival (OS) in patients who did not achieve effective cytoreduction
was comparable to those with effective cytoreduction at 60% and
50%, respectively. The one year OS was 22%. One patient is alive
and disease-free with out GVHD at 58 months.
Our findings demonstrate that survival at 100 days and one year
was independent of clofarabine cytoreduction. These results suggest
that effective cytoreduction with clofarabine is not necessary for
a prolonged response in patients with refractory AML. The one-year
OS in this heavily pretreated refractory population is comparable to
published data. Treatment related mortality was high, particularly in
those patients who received myeloablative conditioning which is
attributable to infectious complications. However, clofarabine fol-
lowed by a RIC allogeneic transplant was tolerated and may be asso-
ciated with a prolonged response.
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DOUBLE TRANSPLANT OF UMBILICAL CORD BLOOD STEM CELL OF
UNRELATED DONORS IN THE TREATMENT OF PEDIATRIC PATIENTS
WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND REMISSION.
PILOT STUDY
Olaya-Vargas, A.1, Perez-Garcia, M.1, Gaytan-Morales, F.2, Del
Campo-Martinez, A.1, Aguilar, D.1 1National Pediatric Institute,
Mexico, DF, Mexico; 2Hospital Infantil de Mexico, Federico Gomez,
Mexico, DF, Mexico
Introduction: The possibility of successful transplantation of cord
blood decreases when cellular dose is low and the compatibility are
not match, so you have to look for options to improve the chances
of successful transplantation.
Material and Methods:We performed a pilot study comparing the
transplant that were performed with two units of umbilical cord
blood of unrelated donor in patients with ALL in second remission
and compared with a group of patients who were transplanted with
a single unit of umbilical cord blood, we evaluated the cell dose,
time of graft and overall survival and event-free survival between
both groups.
Results: Was included a total of 5 patients in the transplant group
with 2 units and 10 patients in the group with a single unit. Cell
dose for the first group was 5.3 x 10e6 of mononuclear cells and
the second group 3.5 x 10e6 mononuclear cells per kilogram of
body weight (p 5 0.16), in all cases histocompatibility was 4 / 6 for
the first group, second group compatibility was 4 / 6 in 5 cases, 5 /
6 in 4 and 6 / 6 in 1 case. Graft was achieved in 100% of patients
in group 1, group 2 graft failure was reported in 2 patients with graft
histocompatibility 4/6. The time of the grafting for the first group
was 17 days and for group 2 was 32 days (p 0.02), 4 of 5 patients
who were transplanted with 2 units of umbilical cord blood are alive
and disease free and in the second group only 5 of 10 patients are
alive and disease free at 12 month follow-up.
Conclusion: The Transplant 2 units of umbilical cord blood in this
pilot study demonstrated to be an appropriate option for improving
the performance of recovery time and better survival.
